Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

ConditionsColorectal Cancer Metastatic Chemotherapy Targeted Therapy Immunotherapy Radiotherapy, Intensity-Modulated

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorSun Yat-sen University

About this trial

The current phase 2, double cohort clinical trial was designed to determine the effectiveness of Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab with/without involved lesions irradiation as 3rd- or later-line therapy for advanced MSS/pMMR colorectal cancer.

Eligibility criteria

Qualifiers

patients with advanced colorectal adenocarcinoma of MSS/pMMR confirmed by histologic or cytologic diagnosis;

aged 18 years and older;

have a quality of life score of 0-1 according to the Eastern Cooperative Oncology Group (ECOG);

can take oral medications;

Disqualifiers

prior application of trefluridine tepidopyrimidine;

prior application of PD-1 or PD-L1 monoclonal antibody;

extensive bone metastases;

extensive peritoneal metastases;

Trial design

Treatments tested in this trial

Trifluorouracil tepidopyrimidine
Bevacizumab
Sindilizumab
IMRT

Treatment groups

57 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov